Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Inclusion Criteria: Men and women at least 18 years old with current clinical manifestation ofnon-ST-segment-elevation myocardial infarction (heart attack) according to the followingthree criteria:

• current symptoms of cardiac ischemia (chest pain leading to cardiac ischemia or heartattack) AND

• either of the following:

• concurrent elevation of troponin I or T, or of creatine kinase - myocardial band (CK-MB) to a level above the upper limit of normal, OR

• concurrent appropriate electrocardiographic evidence AND

• any one (or more) of the following:

• age >= 55 years

• documented history of prior heart attack or coronary revascularization (eg,angioplasty [PCI], coronary artery replacement [CABG])

• diabetes (documented use of insulin or oral hypoglycemic[s])

• documented history of peripheral arterial disease

Exclusion Criteria:

• history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor,or aneurysm

• any bleeding disorder or abnormality

• sustained severe hypertension or valvular heart disease

• current or recent platelet count <100,000 mm^3

• planned or ongoing treatment with a blood thinning medication

• pregnancy

• any significant medical or physiological condition or abnormality that could put thesubject at increased risk or limit the subject's ability to participate for theduration of the study